Skip to main content
All homeSLU Newslink home
Story
37 of 50

SLU Research: PTSD Is a Modifiable Risk Factor for Type 2 Diabetes, Related Adverse Outcomes

A Saint Louis University study, published online Aug. 13 in JAMA Network Open, shows that treating post-traumatic stress disorder is associated with better overall well-being and lower risk of some chronic health conditions, including type 2 diabetes.

ST. LOUIS — Patients with post-traumatic stress disorder (PTSD) and type 2 diabetes have worse glycemic control, increased risk of hospitalization, and poorer self-reported health compared with type 2 diabetes alone, according to a Saint Louis University study.

The study, published online Aug. 13 in JAMA Network Open, shows that treating PTSD is associated with better overall well-being and lower risk of some chronic health conditions, including type 2 diabetes. 

A photo of said Jeffrey Scherrer, Ph.D.

Jeffrey Scherrer, Ph.D., professor of family and community medicine and professor of psychiatry and behavioral neuroscience at Saint Louis University School of Medicine. Scherrer is also co-director of research for SLU’s Advanced HEAlth Data Research Institute. SLU file photo.

“To our knowledge, this is the first evidence that PTSD is a modifiable risk factor, albeit a modest one, for some adverse diabetes outcomes such as microvascular complications,” said Jeffrey Scherrer, Ph.D., professor of family and community medicine and professor of psychiatry and behavioral neuroscience at Saint Louis University School of Medicine, the paper’s senior author. 

Scherrer is also co-director of research for SLU’s Advanced HEAlth Data (AHEAD) Research Institute, a center that addresses public health issues to improve patient health outcomes through data-driven innovation.

"This is further evidence that we should not separate mental from physical health. Treating the whole patient with comorbid PTSD and diabetes should address both conditions to optimize outcomes. Screening for and treating PTSD as part of diabetes care may lead to better clinical outcomes for both conditions," he said. 

In this retrospective study, Scherrer and his co-authors collected patient data from 2011 to 2022 from the Veterans Health Administration (VHA). The data sets were comprised of 10,002 VHA patients, ages 18 to 80, with comorbid PTSD and type 2 diabetes.

Scherrer and his co-authors observed that when patients’ PTSD improved to a level where they no longer met the criteria for PTSD, that improvement was associated with an 8% reduction in risk for microvascular complications compared to those who continued to meet the criteria associated with a PTSD diagnosis. Among those ages 18-49, but not among older patients, no longer meeting PTSD criteria was linked to a significantly lower risk of insulin initiation and all-cause mortality.

PTSD is a metabolic disease related to the body’s inflammatory response. Scherrer and his co-authors found that it is possible that physiological abnormalities in the hypothalamic-pituitary-adrenal axis, changes in metabolic hormones, poor diet and a lack of exercise could explain the connection between PTSD and prediabetes and type 2 diabetes.

Other authors include Joanne Salas, of the AHEAD Research Institute, Saint Louis University School of Medicine; Wenjin Wang, of the Department of Family and Community Medicine, Saint Louis University School of Medicine; Kenneth E. Freedland, Ph.D., of the Department of Psychiatry, Washington University School of Medicine; Patrick J. Lustman, Ph.D., of the Department of Psychiatry, Washington University School of Medicine; Paula P. Schnurr, Ph.D., of the National Center for PTSD, White River Junction, Vermont, and the Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; Beth E. Cohen, M.D., of the Department of Medicine, University of California San Francisco School of Medicine and San Francisco VA Medical Center, San Francisco, California; Allan S. Jaffe, M.D. of the Department of Cardiovascular Medicine and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; Matthew J. Friedman, MD, Ph.D., of the Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.

This study was supported by grant R01HL160553 from the National Heart, Lung, and Blood Institute. 

Latest Newslink